Query: stroke

Filtered By:
Source: American Heart Journal

This page shows you your search results in order of date. This is page number 5.

Order by Relevance | Date

Total 410 results found since Jan 2013.

Effect of High-Dose Oral Multi-Vitamins and Minerals in Participants Not Treated with Statins in the Randomized Trial to Assess Chelation Therapy
Conclusion and Relevance High-dose oral multi-vitamin and multi-mineral supplementation appear to decrease combined cardiac events in a stable, post-MI population not taking statin therapy at baseline. These unexpected findings are being retested in the ongoing TACT2.
Source: American Heart Journal - September 9, 2017 Category: Cardiology Source Type: research

Outcomes of Cardiac Pacing in Adult Patients After a Fontan Operation
Conclusions More than one-third of adult Fontan patients referred to Mayo Clinic had pacemaker implantation. Epicardial leads were associated with high rate of pacemaker reinterventions but similar DRC rates in comparison to endocardial leads.
Source: American Heart Journal - August 26, 2017 Category: Cardiology Source Type: research

Contemporary rates and correlates of statin use and adherence in non-diabetic adults with cardiovascular risk factors: The KP CHAMP study
Conclusions There remain opportunities for improving prevention in patients at risk for cardiovascular events. Our study identified certain patient subgroups that may benefit from interventions to enhance medication adherence, particularly by minimizing treatment gaps and discontinuation of statin therapy within the first year of treatment.
Source: American Heart Journal - August 24, 2017 Category: Cardiology Source Type: research

International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD, ORBIT-AF I, and ORBIT-AF II Registries
Conclusions Among new-onset AF patients, NOAC use has increased and antiplatelet monotherapy has decreased. However, anticoagulation is used frequently in low-risk patients and inconsistently in those at high-risk of stroke. Significant geographic variability in anticoagulation persists and represents an opportunity for improvement.
Source: American Heart Journal - August 24, 2017 Category: Cardiology Source Type: research

Edoxaban for the Management of Elderly Japanese Patients with Atrial Fibrillation Ineligible for Standard Oral Anticoagulant Therapies: Rationale and Design of the ELDERCARE-AF Study
Publication date: Available online 24 August 2017 Source:American Heart Journal Author(s): Ken Okumura, Gregory Y.H. Lip, Masaharu Akao, Kimihiko Tanizawa, Masayuki Fukuzawa, Kenji Abe, Masahiro Akishita, Takeshi Yamashita Edoxaban—a nonvitamin K antagonist oral anticoagulant (NOAC)— 60-mg and 30-mg once-daily dose regimens are noninferior vs well-managed warfarin for the prevention of stroke or systemic embolic events (SEE) with less major bleeding in patients with nonvalvular atrial fibrillation (NVAF). There are no published data from phase 3 clinical trials specifically evaluating the use of NOACs in elderly NVAF ...
Source: American Heart Journal - August 24, 2017 Category: Cardiology Source Type: research

Atrial Fibrillation Decision Support Tool: Population Perspective
Conclusions Availability of DOACs increases the proportion of patients for whom oral anticoagulation therapy is recommended in a real-world cohort of AF patients and increased projected QALYs by more than 1500 when all patients are receiving thromboprophylaxis as recommended by the AFDST compared with current treatment.
Source: American Heart Journal - August 23, 2017 Category: Cardiology Source Type: research

Outcomes in elderly and young patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with bivalirudin versus heparin: pooled analysis from the EUROMAX and HORIZONS-AMI trials
Conclusions In a large group of elderly patients enrolled in the EUROMAX and HORIZONS-AMI trials, bivalirudin was associated with lower 30-day rates of non-CABG major bleeding, subacute ST and NACE, with similar 30-day rates of acute ST and mortality.
Source: American Heart Journal - August 18, 2017 Category: Cardiology Source Type: research

Long-Term Outcomes of Bypass Grafting Versus Drug-Eluting Stenting for Left Main Coronary Artery Disease: Results from the IRIS-MAIN Registry
Conclusions Among patients with significant LMCAD, the long-term risk of the composite outcome of death, myocardial infarction, or stroke was similar between CABG and PCI. Clinical variables that differentially predict adverse outcomes might be useful in triaging appropriate revascularization strategy
Source: American Heart Journal - August 10, 2017 Category: Cardiology Source Type: research

Association between Influenza Vaccination and Reduced Risks of Major Adverse Cardiovascular Events in Elderly Patients
Conclusions Results of this study suggest that influenza vaccination is associated with reduced primary MACE risks in the elderly population, including those with ILI.
Source: American Heart Journal - August 2, 2017 Category: Cardiology Source Type: research

Soluble endothelial cell-selective adhesion molecule and incident cardiovascular events in a multiethnic population
Conclusions sESAM but not sICAM-1 or sVCAM-1 levels are associated with incident ASCVD. Further studies are warranted to investigate the role of sESAM in ASCVD.
Source: American Heart Journal - July 18, 2017 Category: Cardiology Source Type: research

Impact of atrial fibrillation on outcomes of patients treated by transcatheter aortic valve implantation: A systematic review and meta-analysis
Conclusions AF is associated with impaired outcomes after TAVI, including mortality, stroke and - limited to new-onset AF - major bleedings. Compared to pre-existing AF, new-onset AF correlates with higher risk of early stroke and major bleedings. Improved management of AF in the TAVI setting, including tailored antithrombotic treatment strategies, remain a relevant need.
Source: American Heart Journal - July 15, 2017 Category: Cardiology Source Type: research

Cumulative Psychological Stress and Cardiovascular Disease Risk in Middle Aged and Older Women: Rationale, Design and Baseline Characteristics
This study prospectively follows 25,335 women (mean age 72.2 ± 6.04 years) without CVD who returned a short mailed stress questionnaire at baseline and 3 years of follow-up inquiring about their experiences with stress including perceived stress, work stress, work-family spillover, financial stress, traumatic and major life events, discrimination and neighborhood environment/stressors. Other domains ascertained were sleep, anger, cynical hostility, depression, anxiety, social support, intimate partner relations, volunteer and social activities. Higher levels of cumulative stress were associated with younger age and black ...
Source: American Heart Journal - June 28, 2017 Category: Cardiology Source Type: research

Soluble Endothelial Cell-Selective Adhesion Molecule and Incident Cardiovascular Events in a Multi-Ethnic Population
Conclusions sESAM but not sICAM-1 or sVCAM-1 levels are associated with incident ASCVD. Further studies are warranted to investigate the role of sESAM in ASCVD.
Source: American Heart Journal - June 23, 2017 Category: Cardiology Source Type: research

Growth-Differentiation Factor 15 and Risk of Major Bleeding in Atrial Fibrillation: Insights from the RE-LY Trial
Conclusions In patients with AF, GDF-15 is an independent risk indicator for major bleeding and all-cause mortality, but not for stroke. Therefore, GDF-15 seems useful as a specific marker of bleeding in patients with AF on oral anticoagulant treatment.
Source: American Heart Journal - June 8, 2017 Category: Cardiology Source Type: research

Clinical outcomes with percutaneous coronary revascularization vs coronary artery bypass grafting surgery in patients with unprotected left main coronary artery disease: A meta-analysis of 6 randomized trials and 4,686 patients
Conclusions In patients undergoing revascularization for ULMCAD, PCI was associated with similar rates of mortality compared with CABG at a median follow-up of 39 months, but with an interaction effect suggesting relatively lower mortality with PCI in patients with low SYNTAX score and relatively lower mortality with CABG in patients with high SYNTAX score. Both procedures resulted in similar long-term composite rates of death, myocardial infarction, or stroke, with PCI offering an early safety advantage and CABG demonstrating greater durability.
Source: American Heart Journal - June 2, 2017 Category: Cardiology Source Type: research

Probing oral anticoagulation in patients with atrial high rate episodes: Rationale and design of the Non –vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH–AFNET 6) trial
Conclusion NOAH–AFNET 6 will provide robust information on the effect of oral anticoagulation in patients with atrial high rate episodes detected by implanted devices. Graphical abstract
Source: American Heart Journal - May 24, 2017 Category: Cardiology Source Type: research

Clinical Outcomes with Percutaneous Coronary Revascularization versus Coronary Artery Bypass Grafting Surgery in Patients with Unprotected Left Main Coronary Artery Disease: A Meta-Analysis of Six Randomized Trials and 4686 Patients
Conclusions In patients undergoing revascularization for ULMCAD, PCI was associated with similar rates of mortality compared to CABG at a median follow-up of 39 months, but with an interaction effect suggesting relatively lower mortality with PCI in low SYNTAX score patients and relatively lower mortality with CABG in high SYNTAX score patients. Both procedures resulted in similar long-term composite rates of death, MI or stroke, with PCI offering an early safety advantage and CABG demonstrating greater durability.
Source: American Heart Journal - May 19, 2017 Category: Cardiology Source Type: research

Cardiovascular events and hospital resource utilization pre – and post–transcatheter mitral valve repair in high–surgical risk patients
Conclusions MitraClip was associated with a reduced rate of all-cause and HF hospitalizations and an increased rate of bleeding hospitalizations. One-year Medicare costs were reduced in those who survived a full year after the MitraClip procedure. Payors and providers seeking to reduce HF hospitalizations and associated Medicare costs may consider MitraClip among appropriate patients likely to survive 1 year.
Source: American Heart Journal - May 10, 2017 Category: Cardiology Source Type: research

Probing oral anticoagulation in patients with atrial high rate episodes. Rationale and design of the Non vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH – AFNET 6) trial
Conclusion NOAH – AFNET 6 will provide robust information on the effect of oral anticoagulation in patients with atrial high rate episodes detected by implanted devices. Graphical abstract
Source: American Heart Journal - May 4, 2017 Category: Cardiology Source Type: research

Recurrent MI and stroke post –acute coronary syndrome: Which is the lesser evil?
Publication date: May 2017 Source:American Heart Journal, Volume 187 Author(s): Shahar Lavi, Vladimír Džavík
Source: American Heart Journal - April 26, 2017 Category: Cardiology Source Type: research

Rationale and design of the Apixaban for the reduction of thrombo-embolism in patients with Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial
Publication date: Available online 24 April 2017 Source:American Heart Journal Author(s): Renato D. Lopes, Marco Alings, Stuart J. Connolly, Heather Beresh, Christopher B. Granger, Juan Benezet Mazuecos, Giuseppe Boriani, Jens C. Nielsen, David Conen, Stefan H. Hohnloser, Georges H. Mairesse, Philippe Mabo, A. John Camm, Jeffrey S. Healey Device-detected subclinical atrial fibrillation (AF) refers to infrequent, short-lasting, asymptomatic AF that is detected only with long-term continuous monitoring. Subclinical AF is common and associated with an increased risk of stroke; however, the risk of stroke with subclinical AF ...
Source: American Heart Journal - April 24, 2017 Category: Cardiology Source Type: research

Cangrelor reduces the risk of ischemic complications in patients with single-vessel and multi-vessel disease undergoing percutaneous coronary intervention: Insights from the CHAMPION PHOENIX trial
Conclusion In the CHAMPION PHOENIX trial, MVD and SVD patients had similar ischemic outcomes at 48hours and 30days. Cangrelor consistently reduced ischemic complications in both SVD and MVD patients without a significant increase in GUSTO severe bleeding. Clinical perspectives What's known? Cangrelor is a novel, intravenous, potent, and rapidly acting P2Y12 inhibitor that has been demonstrated to reduce the rate of ischemic events at 48hours in patients who received PCI compared with clopidogrel. What's new? In contrast to prior studies, we found that in this modern cohort, patients with SVD and MVD had a similar risk of i...
Source: American Heart Journal - April 18, 2017 Category: Cardiology Source Type: research

One-year mortality outcomes and hospital readmissions of patients admitted with acute heart failure: Data from the Trivandrum Heart Failure Registry in Kerala, India
Conclusion In the THFR, one of three HF patients died within one-year of follow-up during their productive life years. Sub-optimal adherence to guideline-directed treatment is associated with increased propensity of readmission and death. Quality improvement programs aiming to improve adherence to guideline based therapy and reducing readmission may result in significant survival benefits in the relatively younger cohort of HF patients in India. Graphical abstract
Source: American Heart Journal - April 2, 2017 Category: Cardiology Source Type: research

Use of prasugrel vs clopidogrel and outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention in contemporary clinical practice: Results from the PROMETHEUS study
Conclusions In contemporary clinical practice, patients receiving prasugrel tend to have a lower-risk profile compared with those receiving clopidogrel. The lower ischemic and bleeding events associated with prasugrel use were no longer evident after accounting for these baseline differences.
Source: American Heart Journal - April 1, 2017 Category: Cardiology Source Type: research

Dual Antiplatelet Therapy in Patients with Diabetes and Acute Coronary Syndromes Managed without Revascularization
Conclusions Among NSTE ACS patients managed medically without revascularization, patients with DM had a higher risk of ischemic events that was amplified among those treated with insulin. There was no differential treatment effect with a more potent DAPT regimen of aspirin + prasugrel vs. aspirin + clopidogrel.
Source: American Heart Journal - March 28, 2017 Category: Cardiology Source Type: research

Rationale and Design of Family-Based Approach in a Minority Community Integrating Systems –Biology for Promotion of Health (FAMILIA)
Conclusion The FAMILIA studies seek to demonstrate that targeting a younger age group (3-5 years) and using a family-based approach may be a critical strategy in promoting cardiovascular health across the life-span.
Source: American Heart Journal - March 25, 2017 Category: Cardiology Source Type: research

A prospective, randomized, open-label trial of 6-month versus 12-month dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction: Rationale and design of the “DAPT-STEMI trial”
Publication date: June 2017 Source:American Heart Journal, Volume 188 Author(s): Elvin Kedhi, Enrico Fabris, Martin van der Ent, Mark W. Kennedy, Pawel Buszman, Clemens von Birgelen, Stéphane Cook, Hans Wedel, Felix Zijlstra Background The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention with second-generation drug eluting stents (DESs) is unclear. Because prolonged DAPT is associated with higher bleeding risk and health care costs, establishing optimal DAPT duration is of paramount importance. No other randomized controlled trials have evaluated the safety of shorter DAPT dur...
Source: American Heart Journal - March 21, 2017 Category: Cardiology Source Type: research

The Assessment of the Watchman Device in Patients Unsuitable for Oral Anticoagulation (ASAP-TOO) trial
Publication date: Available online 15 March 2017 Source:American Heart Journal Author(s): David R. Holmes, Vivek Y. Reddy, Maurice Buchbinder, Kenneth Stein, Myriah Elletson, Martin W. Bergmann, Boris Schmidt, Jacqueline Saw Background Oral anticoagulants (OACs) reduce stroke risks with nonvalvular atrial fibrillation (AF); however, they are underused because of absolute or relative contraindications due to real or perceived risk of bleeding. Although left atrial appendage closure is increasingly performed in OAC-ineligible patients, this has not been studied in a randomized controlled trial. Study objectives The ASAP-TOO...
Source: American Heart Journal - March 16, 2017 Category: Cardiology Source Type: research

The effects of sacubitril/valsartan on coronary outcomes in PARADIGM-HF
Conclusions Compared with enalapril, sacubitril/valsartan reduced the risk of both the primary endpoint and a coronary composite outcome in PARADIGM-HF. Additional studies on the effect of sacubitril/valsartan on atherothrombotic outcomes in high risk patients are merited.
Source: American Heart Journal - March 15, 2017 Category: Cardiology Source Type: research

Cangrelor reduces the risk of ischemic complications in patients with single and multi-vessel disease undergoing PCI: insights from the CHAMPION PHOENIX Trial
Conclusion In the CHAMPION-PHOENIX trial, MVD and SVD patients had similar ischemic outcomes at 48hours and 30days. Cangrelor consistently reduced ischemic complications in both SVD and MVD patients without a significant increase in GUSTO severe bleeding. Clinical Perspectives. What's known? Cangrelor is a novel, intravenous, potent, and rapidly-acting P2Y12 inhibitor, that has been demonstrated to reduce the rate of ischemic events at 48hours in patients who received PCI compared with clopidogrel. What's new? In contrast to prior studies, we found that in this modern cohort, patients with SVD and MVD had a similar risk of...
Source: American Heart Journal - March 10, 2017 Category: Cardiology Source Type: research

Rationale and Design of Family-Based Approach in a Minority Community Integrating Systems-Biology for Promotion of Health (FAMILIA)
Conclusion The FAMILIA studies seek to demonstrate that targeting a younger age group (3–5 years) and utilizing a family-based approach may be a critical strategy in promoting cardiovascular health across the lifespan.
Source: American Heart Journal - February 22, 2017 Category: Cardiology Source Type: research

An Examination of the Relationship between Serum Uric Acid Level, a Clinical History of Gout, and Cardiovascular Outcomes among Patients with Acute Coronary Syndrome
Conclusions In patients with ACS, increasing levels of sUA are associated with an elevated risk of cardiovascular events, regardless of a clinical diagnosis of gout. Further investigation is warranted to determine the mechanism behind this relationship and to delineate whether sUA is an appropriate therapeutic target to reduce cardiovascular risk.
Source: American Heart Journal - February 21, 2017 Category: Cardiology Source Type: research

Recurrent MI and stroke post acute coronary syndrome: which is the lesser evil?
Publication date: Available online 21 February 2017 Source:American Heart Journal Author(s): Shahar Lavi, Vladimír Džavík
Source: American Heart Journal - February 21, 2017 Category: Cardiology Source Type: research

Use of Prasugrel versus Clopidogrel and Outcomes in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention in Contemporary Clinical Practice: Results from the PROMETHEUS Study
Conclusions In contemporary clinical practice, patients receiving prasugrel tend to have a lower-risk profile compared with those receiving clopidogrel. The lower ischemic and bleeding events associated with prasugrel use were no longer evident after accounting for these baseline differences.
Source: American Heart Journal - February 21, 2017 Category: Cardiology Source Type: research

Differential Occurrence, Profile, and Impact of First Recurrent Cardiovascular Events After an Acute Coronary Syndrome
Conclusions Approximately 9% of patients experienced a first cardiovascular event in the post-ACS setting during a median follow-up of 1year. While the profile and prognostic implications of stroke versus MI as the first nonfatal event differ substantially, approximately one-third of these patients experienced a second event, typically soon after the first event. These findings have implications for improving post-ACS care and influencing the design of future cardiovascular trials.
Source: American Heart Journal - February 21, 2017 Category: Cardiology Source Type: research

A Prospective, Randomized, Open Label Trial of 6Months vs. 12Months Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation In ST-elevation Myocardial Infarction: Rationale and design of the “DAPT-STEMI trial”
Publication date: Available online 20 February 2017 Source:American Heart Journal Author(s): Elvin Kedhi, Enrico Fabris, Martin van der Ent, Mark Kennedy, Pawel Buszman, Clemens von Birgelen, Stéphane Cook, Hans Wedel, Felix Zijlstra Abstract. Background The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) with second-generation drug eluting stents (DES) is unclear. Because prolonged DAPT is associated with higher bleeding risk and health care costs, establishing optimal DAPT duration is of paramount importance. No other randomized controlled trials have evaluated the sa...
Source: American Heart Journal - February 21, 2017 Category: Cardiology Source Type: research

Baseline Characteristics of Patients Enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)
Conclusions EXSCEL is one of the largest global GLP-1RA trials, evaluating the safety and efficacy of EQW with a broad patient population that may extend generalizability compared to prior GLP-1RA trials (ClinicalTrials.gov number, NCT01144338).
Source: American Heart Journal - February 13, 2017 Category: Cardiology Source Type: research

Association of Measured Platelet Reactivity with Changes in P2Y12 Receptor Inhibitor Therapy and Outcomes Following Myocardial Infarction: Insights into Routine Clinical Practice from the TRANSLATE-ACS Study
Conclusions Only one-third of PCI-treated MI patients with high on-clopidogrel platelet reactivity were switched to a more potent P2Y12 receptor inhibitor. Intensification of antiplatelet therapy was associated with lower risk of ischemic events at 1year among HPR patients.
Source: American Heart Journal - February 11, 2017 Category: Cardiology Source Type: research

Rationale and design of the Coronary Computed Tomographic Angiography for Selective Cardiac Catheterization: Relation to Cardiovascular Outcomes, Cost Effectiveness and Quality of Life (CONSERVE) trial
Conclusion The CONSERVE trial will determine whether selective catheterization strategy, based on initial CCTA in patients being referred to ICA, is safe and effective.
Source: American Heart Journal - February 4, 2017 Category: Cardiology Source Type: research

Rationale and design of the Medication adherence Improvement Support App For Engagement —Blood Pressure (MedISAFE-BP) trial
Discussion The MedISAFE-BP trial is the first study to rigorously evaluate an mhealth application's effect on blood pressure and medication adherence. The results will inform the potential effectiveness of this simple system in improving cardiovascular disease risk factors and clinical outcomes.
Source: American Heart Journal - February 3, 2017 Category: Cardiology Source Type: research

Transradial access and the risk of periprocedural stroke
Publication date: Available online 28 January 2017 Source:American Heart Journal Author(s): Artur Dziewierz, Zbigniew Siudak, Tomasz Rakowski, Dariusz Dudek
Source: American Heart Journal - January 28, 2017 Category: Cardiology Source Type: research

Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes
Conclusions In patients with ACS on dual antiplatelet therapy, spontaneous major bleeding events seem “prognostically equivalent” to spontaneous ischemic complications. This result allows quantitative comparisons between both actual and predicted bleeding and ischemic risks. Our findings help to better define net clinical benefit of antithrombotic treatments and more accurate estimate mortality following ischemic and bleeding events in patients with ACS.
Source: American Heart Journal - January 26, 2017 Category: Cardiology Source Type: research

National Patterns in Intensity and Frequency of Outpatient Care for Apparent Treatment-Resistant Hypertension
In conclusion, many people with UaTRH are not seen more than once per year for hypertension and may benefit from increased care.
Source: American Heart Journal - January 21, 2017 Category: Cardiology Source Type: research

Outcomes in Adult Fontan Patients with Atrial Tachyarrhythmias
Conclusions CA and FC operations are associated with less recurrence of atrial tachyarrhythmia compared with AAD. Atrial tachyarrhythmias are more likely to recur in patients with a longer history of the arrhythmia, and are associated with more adverse events. Early referral to a specialty center for these interventions should be considered.
Source: American Heart Journal - January 2, 2017 Category: Cardiology Source Type: research

Rationale and Design of the CONSERVE Trial: Coronary Computed Tomographic Angiography for Selective Cardiac Catheterization: Relation to Cardiovascular Outcomes, Cost Effectiveness and Quality of Life
Conclusion The CONSERVE trial will determine whether selective catheterization strategy, based upon initial CCTA in patients being referred to ICA, is safe and effective.
Source: American Heart Journal - December 22, 2016 Category: Cardiology Source Type: research

A randomized clinical trial comparing long-term clopidogrel vs aspirin monotherapy beyond dual antiplatelet therapy after drug-eluting coronary stent implantation: Design and rationale of the Harmonizing Optimal Strategy for Treatment of coronary artery stenosis-Extended Antiplatelet Monotherapy (HOST-EXAM) trial
Conclusions The HOST-EXAM will be the first large-scale randomized controlled study to directly compare the efficacy and safety of long-term antiplatelet monotherapy beyond DAPT after DES implantation. This study will provide clinical evidence to establish optimal regimen for long-term antiplatelet therapy after DES implantation.
Source: American Heart Journal - December 21, 2016 Category: Cardiology Source Type: research

Left ventricular mass-geometry and silent cerebrovascular disease: the Cardiovascular Abnormalities and Brain Lesions (CABL) Study
Conclusions LV hypertrophy, both with eccentric or concentric pattern, was significantly associated with subclinical cerebrovascular disease in a multiethnic stroke-free general population. LV geometric patterns may carry different risks for silent cerebrovascular disease in different sex, age, race-ethnic, and body size subgroups.
Source: American Heart Journal - December 21, 2016 Category: Cardiology Source Type: research

Acute Coronary Syndrome Quality Improvement in Kerala (ACS QUIK): Rationale and Design for a Cluster Randomized Stepped Wedge Trial
Publication date: Available online 21 December 2016 Source:American Heart Journal Author(s): Mark D. Huffman, P.P. Mohanan, Raji Devarajan, Abigail S. Baldridge, Dimple Kondal, Lihui Zhao, Mumtaj Ali, Donald M. Lloyd-Jones, Dorairaj Prabhakaran Ischemic heart disease is the leading cause of death in India, and there are likely more myocardial infarctions in India than in any other country in the world. We have previously reported heterogeneous care for patients with myocardial infarction in Kerala, a state in southern India, including both gaps in optimal care and inappropriate care. Based on that prior work, limitations ...
Source: American Heart Journal - December 21, 2016 Category: Cardiology Source Type: research

Rationale and Design of the Medication adherence Improvement Support App For Engagement – Blood Pressure (MedISAFE-BP) Trial
Discussion The MedISAFE-BP trial is the first study to rigorously evaluate an mhealth application's effect on blood pressure and medication adherence. The results will inform the potential effectiveness of this simple system in improving cardiovascular disease risk factors and clinical outcomes.
Source: American Heart Journal - December 10, 2016 Category: Cardiology Source Type: research

A randomized clinical trial comparing long-term clopidogrel versus aspirin monotherapy beyond dual antiplatelet therapy after drug-eluting coronary stent implantation: Design and rationale of the HOST-EXAM trial
Conclusions The HOST-EXAM will be the first large-scale randomized controlled study to directly compare the efficacy and safety of long-term antiplatelet monotherapy beyond DAPT after DES implantation. This study will provide clinical evidence to establish optimal regimen for long-term antiplatelet therapy after DES implantation.
Source: American Heart Journal - December 10, 2016 Category: Cardiology Source Type: research